AAM
EW icon

Archipel Asset Management’s Edwards Lifesciences EW Stock Holding History

Archipel Asset Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-98,928
Closed -$1.08M – 76
2013
Q4 		$1.08M Sell
98,928
-433,512
-81% -$4.89M 0.3% 63
2013
Q3 		$6.18M Buy
+532,440
New +$6.23M 1.27% 42

Other funds holding EW

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Archipel Asset Management's EW Position: Q1 2014 in Review

Archipel Asset Management sold out of Edwards Lifesciences (EW) in Q1 2014, closing a stake of 98,928 shares — an estimated $1.08M sold.

Archipel Asset Management first reported a position in EW in Q3 2013 and held it in 2 quarters. The position peaked at $6.18M in Q3 2013. 410 funds tracked by Wall St. Rank hold EW as of Q1 2014.

  • Archipel Asset Management reported no remaining Edwards Lifesciences position as of Q1 2014 after selling out during the quarter.
  • Archipel Asset Management sold 98,928 Edwards Lifesciences shares in Q1 2014, an estimated $1.08M.
  • Archipel Asset Management first reported a position in Edwards Lifesciences in Q3 2013 and held it in 2 quarters.
  • Archipel Asset Management's Edwards Lifesciences position peaked at $6.18M in Q3 2013.
  • 410 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2014.

Based on Archipel Asset Management's 13F filing for Q1 2014, filed 8 May 2014.